Literature DB >> 18080760

Concurrent inflammatory bowel disease and myelodysplastic syndrome: report of nine new cases and a review of the literature.

Zhifeng Wang1, Yanhua Zhou, Yulan Liu.   

Abstract

Nine patients with concurrent myelodysplastic syndrome (MDS) and inflammatory bowel disease (IBD) were examined. Median age at diagnosis of these patients was similar to the usual age of patients at diagnosis of IBD only. There was a strong predominance of Crohn's disease (seven of nine cases), with an unusually high frequency of colorectal involvement (five of nine cases). Inflammatory bowel disease was diagnosed first in one patient, MDS first in five patients, and both diseases were diagnosed simultaneously in three patients. All patients had moderate or severe anemia. The prognosis of IBD was determined by MDS. These observations suggest that there is an unclear common pathogenesis of IBD and MDS and, consequently that patients with IBD and anemia of non-obvious origin should be evaluated for the presence of MDS.

Entities:  

Mesh:

Year:  2007        PMID: 18080760     DOI: 10.1007/s10620-007-0090-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Concurrent inflammatory bowel disease and myelodysplastic syndromes.

Authors:  G C Harewood; E V Loftus; A Tefferi; W J Tremaine; W J Sandborn
Journal:  Inflamm Bowel Dis       Date:  1999-05       Impact factor: 5.325

2.  The association between the myelodysplastic syndromes and Crohn disease.

Authors:  C Eng; F A Farraye; L N Shulman; M A Peppercorn; C M Krauss; J M Connors; R M Stone
Journal:  Ann Intern Med       Date:  1992-10-15       Impact factor: 25.391

Review 3.  Crohn's disease and the myelodysplastic syndrome.

Authors:  J Castellote; F Porta; E Tuset; R Salinas
Journal:  J Clin Gastroenterol       Date:  1997-06       Impact factor: 3.062

4.  An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

Authors:  W J Sandborn; B G Feagan; S B Hanauer; D H Present; L R Sutherland; M A Kamm; D C Wolf; J P Baker; C Hawkey; A Archambault; C N Bernstein; C Novak; P K Heath; S R Targan
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

5.  Fulminant Crohn's colitis after allogeneic stem cell transplantation.

Authors:  S A Sonwalkar; R M James; T Ahmad; L Zhang; C S Verbeke; D L Barnard; D P Jewell; M A Hull
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

6.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

Review 7.  Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype.

Authors:  T Tani; Y Sakai; Y Shirai; M Ohtake; K Hatakeyama
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

8.  Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation.

Authors:  Markus Ditschkowski; Hermann Einsele; Rainer Schwerdtfeger; Donald Bunjes; Rudolf Trenschel; Dietrich W Beelen; Ahmet H Elmaagacli
Journal:  Transplantation       Date:  2003-05-27       Impact factor: 4.939

9.  The incidence of Crohn's disease in northern Norway from 1983 to 1986. Northern Norway Gastroenterology Society.

Authors:  S Kildebo; R Breckan; K Nordgaard; P G Burhol; R Jorde
Journal:  Scand J Gastroenterol       Date:  1989-12       Impact factor: 2.423

10.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Authors:  P Morel; M Hebbar; J L Lai; A Duhamel; C Preudhomme; E Wattel; F Bauters; P Fenaux
Journal:  Leukemia       Date:  1993-09       Impact factor: 11.528

View more
  5 in total

Review 1.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

Review 2.  Anemia in inflammatory bowel disease: a neglected issue with relevant effects.

Authors:  Danila Guagnozzi; Alfredo J Lucendo
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 3.  Stress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and Maintenance.

Authors:  Thomas Clapes; Stylianos Lefkopoulos; Eirini Trompouki
Journal:  Front Immunol       Date:  2016-11-07       Impact factor: 7.561

4.  The inflammatory cytokine profile of myelodysplastic syndromes: A meta-analysis.

Authors:  Xin Shi; Yanhua Zheng; Li Xu; Chun Cao; Baoxia Dong; Xiequn Chen
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander?

Authors:  Gregorios Christodoulidis; Konstantinos Perivoliotis; Anastasios Manolakis; Alexandros Diamantis; Apostolos Koffas; Dimitrios Magouliotis; Vasiliki Pappi; Dimitrios Zacharoulis
Journal:  Case Rep Gastrointest Med       Date:  2020-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.